@FierceBiotech: AstraZeneca touts arthritis, lupus data with a rosy view of its pipeline. Story | Follow @FierceBiotech
@JohnCFierce: This new company really explains why Boston is where it's at right now in biotech. Article | Follow @JohnCFierce
@DamianFierce: ICYMI: Shire pays $260M for Lumena, getting a rare liver disease treatment and a NASH drug. News | Follow @DamianFierce
@EmilyMFierce: Biochips, bioprinting offer alternative drug testing options. Special report | Follow @EmilyMFierce
> Alnylam ($ALNY) said ALN-AT3, an RNAi treatment for hemophilia and other bleeding disorders, succeeded in a Phase I trial. More
> Santhera's in-development Duchenne muscular dystrophy drug met its primary endpoint in a Phase III trial, boosting muscle strength in boys with the motion-limiting disease. News
> After years of clinical disappointments, Telik ($TELK) has signed a deal to dissolve into MabVax Therapeutics in an all-stock deal. Release
@FierceMedDev: Elixir gets a CE mark for its latest bioresorbable stent. Article | Follow @FierceMedDev
@VarunSaxena2: FDA clears prescription video game for rehabilitation therapy. Story from yesterday | Follow @VarunSaxena2
@MichaelGFierce: 'Smart' Drug Delivery Could Aid Cancer Fight. More via Boston College Chronicle | Follow @MichaelGFierce
@EmilyWFierce: Ceterix Orthopaedics ropes in $18M to commercialize its arthroscopic surgical tools. News | Follow @EmilyWFierce
> Medtronic poaches GE exec to lead its $1.5B diabetes biz. Story
> GE Healthcare collaborates with CorTechs Labs on MRI scans. News
Pharma News
@FiercePharma: Lilly decries $450M award in Brazil as based on bad science, fuzzy math. Story | Follow @FiercePharma
@TracyStaton: Pfizer-AstraZeneca recap: Everything you need to know about today's drama, in bite-sized pieces. Report | Follow @TracyStaton
@EricPFierce: Canada orders Biolyse to halt production of injectable drug paclitaxel at a plant in Ontario. Story | Follow @EricPFierce
@CarlyHFierce: Chinese officials to shed some light on Glaxo probe at press briefing. More | Follow @CarlyHFierce
> Merck sells some eye-drug assets to Japan's Santen Pharma for $600M. Article
> Sanofi hopes to make a splash with new meningitis vax initiative. Item
> AstraZeneca trumpets diabetes duo's victory in Phase III. Article
Biotech Research News
> Biochips, bioprinting offer alternative drug testing options. More
> Study: Heart attack stem cell treatment may offer little benefit. Article
> Naturally occurring molecule could treat Type 2 diabetes. News
> Harvard's heart disease-on-a-chip mimics real tissue and disease. Story
> FDA-approved genital warts drug could treat MERS. Article
> UCLA gets $4M for stem cell, digestive disease research. Item
Pharma Manufacturing News
> CSL opens $250M plant for hemophilia treatments. News
> Merck sells Colorado biologics plant to KBI. Report
> Lilly, Dobfar nailed with $450M fine, judge orders Brazilian plant closed. More
> WuXi says it intends to triple capacity at China plant. Article
> Canada regulators stop production at Biolyse Pharma in Ontario. Story